Grippocitron Kids powder 4 g. №10

$15.00

Manufacturer: Ukraine

Increased individual sensitivity to any components of the drug or to other antihistamines; severe violations of liver and kidney function; congenital deficiency of glucose-6-phosphate dehydrogenase (as evidenced by hemolytic anemia); severe cardiac conduction disorders; uncompensated heart failure; hyperthyroidism; obstruction of the bladder neck; pyloroduodenal obstruction; intolerance to fructose, galactose; glucose-galactose malabsorption syndrome, lactase or sucrose-isomaltase deficiency; thrombosis; thrombophlebitis; the tendency to thrombosis; congenital hyperbilirubinemia; glaucoma; alcoholism; violation of hematopoiesis; blood disease; severe leukopenia; anemia; peptic ulcer of the stomach and duodenum in the acute stage.

Category:

Description

Grippocitron Kids Composition
active ingredients: 1 packet contains paracetamol 160 mg, ascorbic acid 50 mg, chlorphenamine maleate 1 mg;

excipients: citric acid; lactose monohydrate, sodium; sucrose; silicon dioxide Neot; polyethylene glycol 4000; flavoring “Lemon” containing maltodextrin, gum arabic, citric acid.

Grippocitron Kids Dosage form
Powder for oral solution.

Basic physical and chemical properties: the contents of the package are a mixture of granules and powder of white or almost white color with a fruity odor.

Grippocitron Kids Pharmacotherapeutic group
Analgesics and antipyretics. ATX code N02B E51.

Pharmacodynamics
Paracetamol has analgesic, antipyretic and mild anti-inflammatory effects. The mechanism of its action is to inhibit the synthesis of prostaglandins and affect the center of thermoregulation in the hypothalamus.

Ascorbic acid (vitamin C), as a key component of the antioxidant and immune defense system, increases the adaptive capabilities of the body, increases its resistance to infections. It actively participates in the regulation of redox processes, in the metabolism of carbohydrates, in the synthesis of steroid hormones, catecholamines and blood clotting. Strengthens collagen synthesis, stimulates regeneration processes, normalizes capillary permeability.

Chlorphenamine maleate is an antihistamine from the class of alkylamines, an H1 receptor blocker. Has antiallergic effect, eliminates rhinorrhea, lacrimation and itching in the eyes and nose. The therapeutic effect develops within one hour after oral administration and lasts for 24 hours.

Pharmacokinetics
The components of the drug are metabolized independently of each other.

After oral administration, paracetamol is rapidly absorbed, mainly in the upper digestive tract. It is quickly distributed in tissues. The blood protein binding is less than 10%. Paracetamol is metabolized in the liver: most of it binds to glucuronic acid, less to sulfuric acid. The half-life of paracetamol is 2-2.5 hours. It increases in individuals with liver disease. Paracetamol is excreted in the urine (85% of a single dose of paracetamol is excreted within 24 hours). The withdrawal significantly worsens with violations of the renal excretory function, which can lead to the accumulation of paracetamol and its metabolic products in the body.

Ascorbic acid is actively absorbed in the small intestine. After oral administration, the maximum concentration in blood plasma is reached after 4 hours. From blood plasma it easily penetrates into leukocytes, platelets and almost all tissues. It undergoes biotransformation in the liver, is excreted in the urine partly unchanged, partly in the form of metabolites.

Chlorphenamine maleate is metabolized in the liver. The half-life is 8 hours. Chlorphenamine maleate and its metabolites are excreted in the urine.

Indications
Prescribed to children aged 2 to 12 years with influenza, SARS and colds to reduce fever, eliminate headaches, pain in muscles and joints, rhinorrhea, sneezing, lacrimation and other symptoms of inflammation of the mucous membranes of the upper respiratory tract and paranasal sinuses.

Contraindications
Hypersensitivity to the components of the drug or to antihistamines;
severe impairment of liver function (> 9 points on the Child-Pugh scale) and / or kidney;
alcoholism;
congenital deficiency of glucose-6-phosphate dehydrogenase;
congenital hyperbilirubinemia (including Gilbert’s syndrome);
violation of hematopoiesis;
blood diseases;
severe leukopenia;
anemia;
tendency to thrombosis;
severe cardiac conduction disorders;
decompensated heart failure;
obstruction of the bladder neck;
pyloroduodenal obstruction;
thrombosis;
thrombophlebitis;
severe forms of diabetes mellitus;
glaucoma;
peptic ulcer of the stomach and duodenum in the acute stage;
children under 2 years of age.
Do not use together with MAO inhibitors (MAO) and within 2 weeks after stopping their use. MAO inhibitors should not be used in conjunction with antihistamines due to the possibility of additive depression of the central nervous system (CNS). They can lengthen and enhance the anticholinergic effect of antihistamines.